Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns.
Urinary polyamine (UPA) excretion patterns were measured in 39 patients with clinically evaluable epithelial ovarian cancer immediately before they were treated with a cycle of chemotherapy and 24-48 h after chemotherapy to ascertain if changes in UPA excretion patterns correlated with eventual response to treatment. Almost all of the 19 patients who responded to chemotherapy had a rise in the excretion of all UPA fractions after treatment while most patients with chemoresistant cancer showed only an increase in the excretion of the putrescine and spermine fractions. However, a two-fold increase in excretion of the spermidine fractions occurred exclusively in patients who would eventually respond to chemotherapy. This phenomenon was not seen in patients with chemoresistant cancer. If, 48 h after chemotherapy, a patient with epithelial ovarian cancer does not show at least a doubling of the urinary levels of spermidine, acetylspermidine or total polyamine excretion that chemotherapy should be stopped since it is unlikely to be effective.
Lawton
F G
FG
Academic Department of Obstetrics and Gynaecology, University of Birmingham, UK.
Griffin
M
M
Slack
J A
JA
Blackledge
G
G
D015317:Biogenic Polyamines / Q000652:urine*; D002277:Carcinoma / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000652:urine
D015317:Biogenic Polyamines